[1] Domingues N, Pires J, Milosevic I, et al. Role of lipids in interorganelle communication[J]. Trends Cell Biol, 2025, 35(1): 46-58.
[2] Han Y Z, Du B X, Zhu X Y, et al. Lipid metabolism disorder in diabetic kidney disease[J]. Front Endocrinol(Lausanne), 2024, 15: 1336402.
[3] Nusken E, Voggel J, Saschin L, et al. Kidney lipid metabolism: impact on pediatric kidney diseases and modulation by early-life nutrition[J]. Pediatr Nephrol, 2025, 40(6): 1839-1852.
[4] Joshi S S, Ruth K, Smaldone M C, et al. Perioperative statin use and acute kidney injury in patients undergoing partial nephrectomy[J]. Kidney Cancer, 2018, 2(1): 47-55.
[5] Chen J, Lin J, Lin C. Serum and urinary biomarkers for predicting acute kidney injury after partial nephrectomy[J]. Clin Invest Med, 2015, 38(3): E82-89.
[6] 卢雅立. 肾部分切除术后急性肾损伤早期的监测指标[J]. 中山大学学报(医学科学版), 2013, 34: 911-916.
[7] Deja S, Fletcher J A, Kim C W, et al. Hepatic malonyl-CoA synthesis restrains gluconeogenesis by suppressing fat oxidation, pyruvate carboxylation, and amino acid availability[J]. Cell Metab, 2024, 36(5): 1088-1104.
[8] Yoon H, Shaw J L, Haigis M C, et al. Lipid metabolism in sickness and in health: Emerging regulators of lipotoxicity[J]. Mol Cell, 2021, 81(18): 3708-3730.
[9] Wang X, Menezes C J, Jia Y, et al. Metabolic inflexibility promotes mitochondrial health during liver regeneration[J]. Science, 2024, 384(6701): eadj4301.
[10] Saper G, Kallmann D, Conzuelo F, et al. Live cyanobacteria produce photocurrent and hydrogen using both the respiratory and photosynthetic systems[J]. Nat Commun, 2018, 9(1): 2168.
[11] Lee J, Roh J L. Cholesterol-ferroptosis nexus: unveiling novel cancer therapeutic avenues[J]. Cancer Lett, 2024, 597: 217046.
[12] Ralto K M, Rhee E P, Parikh S M. NAD(+) homeostasis in renal health and disease[J]. Nat Rev Nephrol, 2020, 16(2): 99-111.
[13] Agrawal S, Zaritsky J J, Fornoni A, et al. Dyslipidaemia in nephrotic syndrome: mechanisms and treatment[J]. Nat Rev Nephrol, 2018, 14(1): 57-70.
[14] Riffelmacher T, Clarke A, Richter F C, et al. Autophagy-dependent generation of free fatty acids is critical for normal neutrophil differentiation[J]. Immunity, 2017, 47(3): 466-480.
[15] Bonora M, Wieckowski M R, Sinclair D A, et al. Targeting mitochondria for cardiovascular disorders: therapeutic potential and obstacles[J]. Nat Rev Cardiol, 2019, 16(1): 33-55.
[16] Dang X, Qin Y, Gu C, et al. Knockdown of tripartite motif 8 protects H9C2 cells against hypoxia/reoxygenation-induced injury through the activation of PI3K/Akt signaling pathway[J]. Cell Transplant, 2020, 29: 963689720949247.
[17] Chen P, Liu W, Wei Y. Ramelteon attenuates renal ischemia and reperfusion injury through reducing mitochondrial fission and fusion and inflammation[J]. Transl Androl Urol, 2023, 12(12): 1859-1870.
[18] Révész C, Kaucsár T, Godó M, et al. Neutrophils and NADPH oxidases are major contributors to mild but not severe ischemic acute kidney injury in mice[J]. Int J Mol Sci, 2024, 25(5):2948.
[19] Wang J X, Bair A M, King S L, et al. Ly6G ligation blocks recruitment of neutrophils via a beta2-integrin-dependent mechanism[J]. Blood, 2012, 120(7): 1489-1498.
[20] Su M, Hu X, Lin J, et al. Identification of candidate genes involved in renal ischemia/reperfusion injury[J]. DNA Cell Biol, 2019, 38(3): 256-262.
[21] Huang M, Pan D, Du Y, et al. Na(+)/Ca(2+) exchanger 1(NCX-1) mediates the anti-apoptotic effect of Akt1 in neonatal rat cardiomyocytes during ischemia/reperfusion[J]. Am J Transl Res, 2016, 8(3): 1369-1378.
[22] Naderi-Meshkin H, Setyaningsih W W. Endothelial cell dysfunction: onset, progression, and consequences[J]. Front Biosci(Landmark Ed), 2024, 29(6): 223.
[23] Raghavan V, Vijayaraghavalu S, Peetla C, et al. Sustained epigenetic drug delivery depletes cholesterol-sphingomyelin rafts from resistant breast cancer cells, influencing biophysical characteristics of membrane lipids[J]. Langmuir, 2015, 31(42): 11564-11573.
[24] Zhao L, Hao Y, Tang S, et al. Energy metabolic reprogramming regulates programmed cell death of renal tubular epithelial cells and might serve as a new therapeutic target for acute kidney injury[J]. Front Cell Dev Biol, 2023, 11: 1276217.
[25] Saliakoura M, Rossi Sebastiano M, Pozzato C, et al. PLCgamma1 suppression promotes the adaptation of KRAS-mutant lung adenocarcinomas to hypoxia[J]. Nat Cell Biol, 2020, 22(11): 1382-1395.
[26] Lawana V, Singh N, Sarkar S, et al. Involvement of c-Abl Kinase in microglial activation of NLRP3 inflammasome and impairment in autolysosomal system[J]. J Neuroimmune Pharmacol, 2017, 12(4): 624-660.
[27] Pefanis A, Ierino F L, Murphy J M, et al. Regulated necrosis in kidney ischemia-reperfusion injury[J]. Kidney Int, 2019, 96(2): 291-301.
[28] Naruse T, Otake H, Takahashi T. Effects of a lysophosphatidic acid receptor 1 antagonist on hypertensive renal injury in Dahl-Iwai salt-sensitive rats[J]. J Pharmacol Sci, 2022, 149(4): 179-188.
[29] Scantlebery A M, Tammaro A, Mills J D, et al. The dysregulation of metabolic pathways and induction of the pentose phosphate pathway in renal ischaemia-reperfusion injury[J]. J Pathol, 2021, 253(4): 404-414.
[30] Soliman E, Elshazly S M, Shewaikh S M, et al. Reno-and hepato-protective effect of allopurinol after renal ischemia/reperfusion injury: crosstalk between xanthine oxidase and peroxisome proliferator-activated receptor gamma signaling[J]. Food Chem Toxicol, 2023, 178: 113868.
[31] Dorotea D, Koya D, Ha H. Recent Insights Into SREBP as a direct mediator of kidney fibrosis via lipid-independent pathways[J]. Front Pharmacol, 2020, 11: 265.
[32] Tang B, Luo Z, Zhang R, et al. An update on the molecular mechanism and pharmacological interventions for Ischemia-reperfusion injury by regulating AMPK/mTOR signaling pathway in autophagy[J]. Cell Signal, 2023, 107: 110665.
[33] Nicholson R J, Holland W L, Summers S A. Ceramides and acute kidney injury[J]. Semin Nephrol, 2022, 42(3): 151281.
[34] Erpicum P, Rowart P, Defraigne J O, et al. What we need to know about lipid-associated injury in case of renal ischemia-reperfusion[J]. Am J Physiol Renal Physiol, 2018, 315(6): F1714-F1719.
[35] Kuchta A, Cwiklińska A, Czaplińska M, et al. Plasma levels of prebeta1-HDL are significantly elevated in non-dialyzed patients with advanced stages of chronic kidney disease[J]. Int J Mol Sci, 2019, 20(5):1202.
[36] Suh S H, Oh T R, Choi H S, et al. Non-high-density lipoprotein cholesterol and cardiovascular outcomes in chronic kidney disease: results from KNOW-CKD study[J]. Nutrients, 2022, 14(18):3792.
[37] Li B, Leung J C K, Chan L Y Y, et al. Tubule-specific deletion of LincRNA-p21ameliorates lipotoxic kidney injury[J]. Mol Ther Nucleic Acids, 2021, 26: 1280-1290.
[38] Kang H M, Ahn S H, Choi P, et al. Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development[J]. Nat Med, 2015, 21(1): 37-46.
[39] Sivarajah A, Chatterjee P K, Hattori Y, et al. Agonists of peroxisome-proliferator activated receptor-alpha(clofibrate and WY14643) reduce renal ischemia/reperfusion injury in the rat[J]. Med Sci Monit, 2002, 8(12): BR532-BR539.
[40] Chen W, Xi X, Zhang S, et al. Pioglitazone protects against renal ischemia-reperfusion injury via the amp-activated protein kinase-regulated autophagy pathway[J]. Front Pharmacol, 2018, 9: 851.
[41] Rojas-Morales P, Leon-Contreras J C, Aparicio-Trejo O E, et al. Fasting reduces oxidative stress, mitochondrial dysfunction and fibrosis induced by renal ischemia-reperfusion injury[J]. Free Radic Biol Med, 2019, 135: 60-67.
[42] Rojas-Morales P, Leon-Contreras J C, Sanchez-Tapia M, et al. A ketogenic diet attenuates acute and chronic ischemic kidney injury and reduces markers of oxidative stress and inflammation[J]. Life Sci, 2022, 289: 120227.